Xangri La

Researchers are studying Deucravacitinib (BMS-986165) to understand its drug levels, effectiveness, and safety in children and adolescents aged 5 to less than 18 years who have juvenile psoriatic arthritis. This condition involves arthritis affecting multiple joints in young patients, and the study is designed as a phase 3, multicenter, double-blind, placebo-controlled, randomized withdrawal trial. The goal is to see how well the medication works and how safe it is in this population. Participants will receive either Deucravacitinib or a placebo, both given at specified doses on specified days. The study includes a withdrawal period starting from week 16 up to week 42, during which researchers will monitor the time to first flare of the disease. This design helps to evaluate the lasting effects and safety of the treatment over time. Throughout the study, participants will be closely monitored for treatment response and safety. Researchers will track disease flares and collect data on how the drug is processed in the body. The total participation duration includes the treatment and withdrawal periods, allowing for thorough assessment of drug efficacy and safety in pediatric patients with juvenile psoriatic arthritis.